3 Complex Generics and Oncology Specialist, Global Generics Major and Cardiovascular and Gastro Brands Leader Stocks With a Strong Future Roadmap: Natco Pharma, Dr. Reddy’s Laboratories and Torrent Pharmaceuticals
- October 26, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Natco Pharma, Dr. Reddy’s Laboratories and Torrent Pharmaceuticals: ROE of 11.1% to 25.5% and FY22 to FY26 revenue CAGR of 12.3% to 21.0%. Prices as of 23 Oct 2026.
Quick Answer
The three oncology, global generic and heart pharma stocks to watch are Natco Pharma, Dr. Reddy’s Laboratories and Torrent Pharmaceuticals. Their return on equity ranges from 11.1% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.3% to 21.0%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Natco Pharma has the fastest revenue growth at 21.0% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
Oncology, global generic and heart pharma stocks let investors follow companies that serve a growing part of the Indian economy. Natco Pharma, Dr. Reddy’s Laboratories and Torrent Pharmaceuticals cover a complex generics and oncology specialist, a global generics major and a cardiovascular and gastro brands leader.
This list covers three oncology, global generic and heart pharma stocks with complete current figures: Natco Pharma, Dr. Reddy’s Laboratories and Torrent Pharmaceuticals. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Oncology, Global Generic and Heart Pharma Stocks?
Oncology, global generic and heart pharma stocks are listed drug makers that sell complex generics, branded prescriptions and active ingredients in India, the United States and other regions. Their earnings depend on launches, approvals, brand strength and export demand.
Oncology, Global Generic and Heart Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Natco Pharma | 791.85 | 15,708 | 13.7 | 36.0 | 15.4 | 0.08 |
| Dr. Reddy’s Laboratories | 1,229.5 | 103,667 | 32.6 | 36.0 | 11.1 | 0.20 |
| Torrent Pharmaceuticals | 4,524.4 | 173,079 | 80.3 | 36.0 | 25.5 | 1.79 |
On valuation, Natco Pharma and Dr. Reddy’s Laboratories trade at a P/E below the industry P/E, while Torrent Pharmaceuticals trades above it, which reflects the growth the market already expects. Readers comparing oncology, global generic and heart pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Oncology, Global Generic and Heart Pharma Stocks Have a Strong Roadmap in India?
Oncology, global generic and heart pharma stocks have a strong roadmap in India because a rich pipeline of complex products, strong prescription brands and wider access to medicines keep lifting the revenue base.
- Complex products. Hard to copy medicines earn better returns.
- Brand strength. Chronic therapy brands retain loyal prescribers.
- Global reach. Launches in regulated markets add revenue.
Why Natco Pharma Features Among These Oncology, Global Generic and Heart Pharma Stocks
Among the oncology, global generic and heart pharma stocks on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.
Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.
The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.
Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.
Why Dr. Reddy’s Laboratories Features Among These Oncology, Global Generic and Heart Pharma Stocks
Among the complex drug and oncology specialist shares on this list, Dr. Reddy’s Laboratories is a Hyderabad-based pharmaceutical company that makes generics, active ingredients and branded products for India and global markets, with a large presence in North America and Europe.
Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%.
The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0.
Roadmap: The company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
What to watch: Monitor launches of complex generics and the progress of biosimilar programmes.
Why Torrent Pharmaceuticals Features Among These Oncology, Global Generic and Heart Pharma Stocks
Among the three companies on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.
The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.
Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore.
Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.
Natco Pharma vs Dr. Reddy’s Laboratories vs Torrent Pharmaceuticals on Key Financials
The table below sets the three oncology, global generic and heart pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Natco Pharma | 2,044 | 4,376 | 21.0% | 1,372 | 31.4% |
| Dr. Reddy’s Laboratories | 22,030 | 35,059 | 12.3% | 4,158 | 11.9% |
| Torrent Pharmaceuticals | 8,705 | 13,886 | 12.4% | 2,138 | 15.4% |
Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Dr. Reddy’s Laboratories has the largest FY26 revenue at Rs 35,059 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with oncology, global generic and heart pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Oncology, Global Generic and Heart Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these oncology, global generic and heart pharma stocks, the main points are: Long-term complex drug and oncology specialist shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory checks. Plant inspections can affect approvals.
- Price pressure. Generic prices abroad can fall.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter oncology, global generic and heart pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Oncology, Global Generic and Heart Pharma Stocks
Oncology, global generic and heart pharma stocks reward investors who follow demand trends, order books and margins together. Natco Pharma, Dr. Reddy’s Laboratories and Torrent Pharmaceuticals each have a clear plan to grow. Based on the 23 October 2026 close, Natco Pharma trades at Rs 791.85, Dr. Reddy’s Laboratories at Rs 1,229.5 and Torrent Pharmaceuticals at Rs 4,524.4.
Download the Univest iOS App or Univest Android App to track oncology, global generic and heart pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are oncology, global generic and heart pharma stocks?
Ans. Oncology, global generic and heart pharma stocks are listed drug makers that sell complex generics, branded prescriptions and active ingredients in India, the United States and other regions. Their earnings depend on launches, approvals, brand strength and export demand. This list looks at three of them, Natco Pharma, Dr. Reddy’s Laboratories and Torrent Pharmaceuticals, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which oncology, global generic and heart pharma stocks are covered in this list?
Ans. This list covers Natco Pharma, Dr. Reddy’s Laboratories and Torrent Pharmaceuticals. Based on the 23 October 2026 close, Natco Pharma traded at Rs 791.85, Dr. Reddy’s Laboratories at Rs 1,229.5 and Torrent Pharmaceuticals at Rs 4,524.4. Their return on equity ranges from 11.1% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.3% to 21.0%.
Why do oncology, global generic and heart pharma stocks have a strong future roadmap in India?
Ans. Oncology, global generic and heart pharma stocks have a strong roadmap in India because a rich pipeline of complex products, strong prescription brands and wider access to medicines keep lifting the revenue base. The main drivers are as follows. Complex products. Hard to copy medicines earn better returns. Brand strength. Chronic therapy brands retain loyal prescribers. Global reach. Launches in regulated markets add revenue. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Natco Pharma performed financially?
Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
How has Dr. Reddy’s Laboratories performed financially?
Ans. Revenue rose from Rs 22,030 crore in FY22 to Rs 35,059 crore in FY26, a compound annual growth rate of 12.3%. Net profit grew from Rs 2,182 crore in FY22 to Rs 4,158 crore in FY26, which works out to a compound annual growth rate of 17.5%. The company has a return on equity of 11.1%, a debt to equity ratio of 0.20 and a market capitalisation of Rs 103,667 crore. The stock trades at a P/E of 32.6, below the industry P/E of 36.0. Looking ahead, the company is widening its product pipeline with complex generics, biosimilars and consumer health, while its domestic business adds steady growth. Investment in research supports a stream of new launches.
How has Torrent Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What risks should investors check before buying oncology, global generic and heart pharma stocks?
Ans. Investors should check a few risks before buying oncology, global generic and heart pharma stocks. Regulatory checks. Plant inspections can affect approvals. Price pressure. Generic prices abroad can fall. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of oncology, global generic and heart pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
